Oncology pipeline
Our in house programs are in oncology, and we are advancing our lead candidate, CPC634, through a Phase 2 clinical trials in patients with ovarian cancer. We are also progressing CPC879, an innovative oligonucleotide based therapeutic into preclinical studies.
CriPec®-based therapeutics
CriPec®-based therapeutics are new drug modality that is designed and engineered to either passively or specifically target defined cells or tissue in the body. They concentrate a drug payload and extend local exposure at the disease site while minimizing adverse effects on healthy tissues.
CriPec® technology platform
Our proprietary polymeric technology platform, CriPec®, enables the rational design and straightforward manufacturing of custom-made nanomedicines. It can be applied to innovative development candidates and in-market drugs to create novel nanomedicines.
CliCr® copper free click chemistry reagent
With CliCr® as one of our proprietary platforms, we offer a powerful copper free click chemistry reagent for the life science industry. The platform is based on TMTHSI.
Partnering Cristal Therapeutics
We have established several industry partnerships to co-create CriPec®-based therapeutics and assess their applicability in a number of therapeutic areas, including oncology and inflammation.
We are actively seeking partnerships for our proprietary inflammation programs.
Leadership team
We have an experienced management team of entrepreneurial life science executives who bring a powerful combination of leadership, scientific, technical, and clinical expertise.
Watch Informa interview with our CEO/CMO, Dr Axel Mescheder at BIOEurope 2018
Latest News
- Cristal Therapeutics announces a publication in ‘Chemical Science’ on CliCr® technology platform, comprising a new class of superior copper free click reagents for conjugation of small molecules, biologics, nanoparticles and other moieties 29 September 2020
- Cristal Therapeutics Awarded Horizon 2020 Grant to Further Develop the CriPec® Nanomedicine Platform 2 July 2020
- Cristal Therapeutics Publishes Positive Data on its CriPec® Nanomedicine Technology in Small 11 May 2020
Events
There are no upcoming events.
© Cristal Therapeutics
Oxfordlaan 55
6229 EV Maastricht
Netherlands
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 784127.